Anti IL-17 therapy rapidly decreases osteoclast activity in psoriatic patients: a novel quality in addition to its efficacy and safety.
Psoriasis is a chronic, immune-mediated, inflammatory skin disease where interleukin-17 plays an important role in the underlying pathogenesis. IL-17A is a key driver of pro- osteoclastogenic process, that is abnormal in psoriatic patients. Aim of this study was to investigate in vivo the capability of secukinumab to influence the osteoclastogenesis in psoriatic patients reporting also our experience regarding the effectiveness and safety profile of this biological treatment. Efficacy and tolerability of secukinumab were evaluated after the induction period and 12 weeks. Moreover, to investigate how the cutaneous clinical improvement impacted also on the osteoclastogenic profile of psoriatic patients, the osteoclastogenic assay was performed in 5 secukinumab-treated psoriatic patients, not including psoriatic arthritis, before and after 5 weeks of therapy. In line with clinical trials, our results confirmed the efficacy, speed of achievement and safety of secukinumab for the treatment of psoriatic patients. Moreover, in our experiments, secukinumab has demonstrated speed of action also on osteoclastogenic process, reducing the number and activity of osteoclasts only after five weeks of treatment.